Hyperactivation of the Insulin-like Growth Factor Receptor I Signaling Pathway Is an Essential Event for Cisplatin Resistance of Ovarian Cancer Cells
Open Access
- 1 April 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (7) , 2996-3003
Abstract
Platinum plays a central role in the therapy of ovarian cancer, and the emergence of platinum resistance is a major obstacle for clinical management of the disease. We treated A2780 ovarian cancer cells by weekly cycles of cisplatin over a period of 6 months and unveiled that enhanced insulin-like growth factor I receptor (IGF-IR) expression and autocrine IGF-I are associated with hyperactivation of the IGF-IR and phosphatidylinositol-3-OH kinase (PI3K) pathways in cisplatin-resistant cells. IGF-IR expression levels increased during treatment cycles and correlated with cisplatin resistance. Purified IGF-I induced cisplatin resistance in diverse ovarian cancer cell lines, and small molecule inhibitors proved that IGF-IR and PI3K are essential for cisplatin resistance. Similar results were obtained with BG-1 ovarian cancer cells. Cytogenetic and array comparative genomic hybridization analyses revealed selection and de novo formation of chromosomal alterations during resistance development. An analysis of gene expression profiles of primary ovarian carcinomas identified the regulatory subunit PIK3R2 of PI3-kinase as a significant negative prognosis factor for ovarian cancer. We conclude that targeting the IGF-IR and the PI3K pathways is a promising new strategy to treat cisplatin-resistant ovarian carcinomas. [Cancer Res 2009;69(7):2996–3003]Keywords
All Related Versions
This publication has 47 references indexed in Scilit:
- IGF-1 Receptor Inhibitors in Clinical Trials—Early LessonsJournal of Mammary Gland Biology and Neoplasia, 2008
- High definition cytogenetics and oligonucleotide aCGH analyses of cisplatin‐resistant ovarian cancer cellsGenes, Chromosomes and Cancer, 2008
- Epidermal Growth Factor Receptor Pathway Analysis Identifies Amphiregulin as a Key Factor for Cisplatin Resistance of Human Breast Cancer CellsJournal of Biological Chemistry, 2008
- An Integrated Genomic-Based Approach to Individualized Treatment of Patients With Advanced-Stage Ovarian CancerJournal of Clinical Oncology, 2007
- Frequent Mutation of the PIK3CA Gene in Ovarian and Breast CancersClinical Cancer Research, 2005
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005
- Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR ComplexScience, 2005
- Insulin-like growth factors and neoplasiaNature Reviews Cancer, 2004
- AKT2 Inhibition of Cisplatin-induced JNK/p38 and Bax Activation by Phosphorylation of ASK1Journal of Biological Chemistry, 2003
- ras mutation and platinum resistance in human ovarian carcinomasin vitroInternational Journal of Cancer, 1998